sacituzumab govitecan
gilead sciences
['neostar', 'breast', 'sacituzumab', 'aura ']
#asco22 | poster 284 | mon 1:27pm cdt
phase 2 study of response-guided neoadjuvant sacituzumab govitecan (immu-132) in patients with localized triple-negative breast cancer: results from the neostar trial.
presenter: laura spring, md 
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.